Stock MB8 MOBERG PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Moberg Pharma AB Deutsche Boerse AG

Equities

MB8

SE0020353928

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 10:05:45 16/07/2024 BST 		5-day change 1st Jan Change
3.148 EUR -0.06% Intraday chart for Moberg Pharma AB +3.35% +129.78%
06-25 Moberg Pharma Raises SEK336 Million from Share Sale MT
05-14 Moberg Pharma AB Elects Jonas Ekblom as Board Member CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 337.9 143.1 228 425 1,713 - -
Enterprise Value (EV) 1 -557.6 143.1 228 425 1,474 1,514 1,713
P/E ratio 0.58 x 15.7 x -11 x -11.4 x -5.24 x -7.34 x -
Yield - - - - - - -
Capitalization / Revenue 21.7 x 2.83 x 1,101 x - 285 x 40.8 x 17.3 x
EV / Revenue -35.8 x 2.83 x 1,101 x - 246 x 36 x 17.3 x
EV / EBITDA 186 x - -12.9 x -16.8 x -40.9 x -72.1 x 59.1 x
EV / FCF - - - -2.7 x -20.5 x -37.8 x 285 x
FCF Yield - - - -37% -4.88% -2.64% 0.35%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 1,867 1,986 9,827 27,961 46,693 - -
Reference price 2 181.0 72.05 23.20 15.20 36.68 36.68 36.68
Announcement Date 27/09/19 09/02/21 07/02/23 13/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net sales 1 15.55 50.49 0.207 - 6 42 99
EBITDA 1 -3 - -17.64 -25.36 -36 -21 29
EBIT 1 -4.22 - -20.23 -27.46 -37 -24 6
Operating Margin -27.13% - -9,771.01% - -616.67% -57.14% 6.06%
Earnings before Tax (EBT) 1 -5.065 - - -25.42 -36 -24 7
Net income 1 558.8 - -15.71 -21.09 -29 -22 5
Net margin 3,592.74% - -7,589.37% - -483.33% -52.38% 5.05%
EPS 2 313.5 4.600 -2.100 -1.330 -7.000 -5.000 -
Free Cash Flow 1 - - - -157.3 -72 -40 6
FCF margin - - - - -1,200% -95.24% 6.06%
FCF Conversion (EBITDA) - - - - - - 20.69%
FCF Conversion (Net income) - - - - - - 120%
Dividend per Share - - - - - - -
Announcement Date 27/09/19 09/02/21 07/02/23 13/02/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 895 - - - 239 199 -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - -157 -72 -40 6
ROE (net income / shareholders' equity) -1.1% - - -3% -4% -3% -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 32.4 - - - - - -
Capex / Sales 208.28% - - - - - -
Announcement Date 27/09/19 09/02/21 07/02/23 13/02/24 - - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.53% 856B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.95% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.66% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.06% 325B
ABBVIE INC. Stock AbbVie Inc.
+9.18% 297B
ROCHE HOLDING AG Stock Roche Holding AG
+5.89% 234B
NOVARTIS AG Stock Novartis AG
+16.53% 226B
AMGEN INC. Stock Amgen Inc.
+15.67% 177B
PFIZER, INC. Stock Pfizer, Inc.
+2.47% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MOB Stock
  4. MB8 Stock
  5. Financials Moberg Pharma AB